gemcitabine/carboplatin

DRUG7 trials

Conditions

Breast CancerColorectal CarcinomaMelanomaMuscle Invasive Bladder Urothelial CarcinomaNon-small Cell Lung CancerNon-small Cell Lung CarcinomaOvarian CancerPancreatic Carcinoma

Early Phase 1

Drug Screening Using IMD in Bladder Cancer

Not yet recruitingNCT06204614

Brigham and Women's HospitalMuscle Invasive Bladder Urothelial Carcinoma

Start: 2024-02-14End: 2025-07-01Target: 18Updated: 2024-01-12

Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

CompletedNCT02009449

Eli Lilly and CompanyBreast Cancer, Colorectal Carcinoma, Melanoma +6

Start: 2013-11-15End: 2023-07-22Updated: 2024-11-15

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

RecruitingNCT02889666

Shanghai Jiao Tong University School of MedicineRecurrent Non-small Cell Lung Cancer

Start: 2008-01-31End: 2027-12-31Target: 500Updated: 2024-04-17

Phase 2

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

CompletedNCT00540358

SanofiBreast Cancer

Start: 2007-10-31End: 2010-06-30Updated: 2012-12-28

Phase 3

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

CompletedNCT00874419

Tongji UniversityNon-small Cell Lung Cancer

Start: 2008-08-31End: 2012-07-31Updated: 2014-09-25

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

CompletedNCT00938652

SanofiBreast Cancer

Start: 2009-07-31End: 2012-02-29Updated: 2013-09-19

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

CompletedNCT01082549

SanofiSquamous Cell Lung Cancer

Start: 2010-03-31End: 2013-04-30Updated: 2016-03-17

UNC Libraries2021-12-07

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

Investigational New Drugs2020-09-1014 citations

Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).

Journal of Clinical Oncology2020-05-202 citations

Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

Journal of Clinical Oncology2020-05-201 citations

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Journal of Clinical Oncology2020-02-191 citations

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

2019-09-25100 citations

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-013 citations

Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of Oncology2018-10-012 citations

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of Oncology2018-10-011 citations

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

Annals of Oncology2018-10-01

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Annals of Oncology2018-10-01

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Journal of Clinical Oncology2018-05-2010 citations

Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2018-05-207 citations

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.

Journal of Clinical Oncology2018-05-203 citations

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer

BMJ Open2018-04-0113 citations

Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2018-02-0113 citations

PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.

Journal of Clinical Oncology2017-05-204 citations

Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2017-05-202 citations

Efficacy and safety of pegylated human IL-10 (AM0010) in combination with an anti-PD-1 in renal cell cancer.

Journal of Clinical Oncology2017-05-201 citations

Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.

Journal of Clinical Oncology2017-05-20

13 more papers not shown